Sirnaomics, a US-based RNAi therapeutics developer backed by vaccine producer Walvax Biotechnology and conglomerates China Resources Group and Charoen Pokphand Group, has closed a $105m series E round.
Investment manager Rotating Boulder Fund led the round and was joined by unspecified new and existing investors.
Founded in 2007, Sirnaomics is developing drug treatments based on a biological process called RNA interference (RNAi), in which small interfering RNAs degrade messenger RNA molecules to regulate gene expression.
The company’s frug candidates are intended to address a number of health conditions including cancer, fibrosis, viral infections and metabolic diseases. The funding will support the development of those candidates, and also plans to strengthen its technology platform and manufacturing capacity.
Sirnaomics collected $105m in a series D round in October 2020 co-led by Walvax Biotechnology, Rotating Boulder Fund and Sunshine Riverhead Capital, a private equity vehicle for insurer Sunshine Insurance. It was also backed by Sangel Capital, Longmen Capital, HongTao Capital and Alpha Win Capital.
CR-CP Life Sciences Fund, a $300m investment fund managed by China Resources Group and Charoen Pokphand Group, contributed to a $47m series C round for the company that closed in April 2019.
The series C round also featured Rolling Boulder, Sangel Capital, Rich Yield Capital, Legend Sky Investment, Yuexiu New Industrial Investment, HuaKong Equity Investment and Qianhai Shenghui Investment. Sirnaomics had previously raised $25m from investors including Value Measured Investment.